Is ruxolitinib/ruxolitinib cream effective in treating vitiligo?

Ruxolitinib is a topical JAK1/2 inhibitor that has attracted widespread attention in the field of vitiligo treatment in recent years. Especially for non-segmental vitiligo, the effect of this drug has shown a positive trend in clinical studies. It reduces the overexpression of pro-inflammatory cytokines by inhibiting JAK-STAT signal transduction downstream of the interferon-γ signaling pathway, thereby contributing to the recovery and regeneration of pigment cells and improving skin pigmentation abnormalities. Compared with traditional hormone-based treatment options, ruxolitinib cream provides a new non-hormone targeted treatment method, and the risk of long-term skin adverse reactions is relatively low.

In two pivotalPhase III clinical studies (TRuE-V1 and TRuE-V2), ruxolitinib cream showed significant improvement in efficacy. After about one-third of users continued to use it for 6 months, their facial white spot area pigment recovery reached F-VASI75, that is, the improvement reached more than 75%. This number is much higher than the approximately 10% in the placebo group, showing that the drug has a clear advantage in restoring white spots on the face. In terms of whole-body pigmentation improvement, about 22% of patients reached the 50% improvement standard in T-VASI score, which was also much better than the 6% in the control group. This trend toward gradual restoration of pigment also reflects the unique role of JAK inhibitors in modulating abnormal immune system responses.

It is worth noting that as a prescription drug, the efficacy of ruxolitinib cream is based on continuous and regular use. Most patients will need at least 8 to 12 weeks before they begin to see significant changes in the initial stage of use. Individual differences may also affect the efficacy of the drug, such as the duration of vitiligo, distribution of skin lesions, skin type, etc. In addition, because the drug acts on the immune pathway, it is not suitable for use in infectious skin lesions. Doctors will evaluate whether it is suitable for use based on the patient's overall health.

Reference: https://www.opzelura.com/